About GSK
Industry:
Pharmaceuticals
Founded:
2000
Founders:
Merger of Glaxo Wellcome and SmithKline Beecham
Status:
Public (NYSE: GSK)
Funding & Growth
Total Raised:
N/A
Valuation:
$80B+ market cap
Stage:
Public
Key Investors:
Public markets
✓ Pros
- • Strong vaccines and specialty pharma portfolio
- • Heavy investment in AI/ML for drug discovery
- • Global presence with US hubs
- • Good work-life balance
- • Partnerships with 23andMe, AI companies
✗ Cons
- • Recent spin-off (Haleon) transition
- • UK headquarters (timezone challenges)
- • Large company bureaucracy
- • Restructuring in some areas